Llwytho...
TARGETED THERAPIES: Afatinib—new therapy option for EGFR-mutant lung cancer
On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of pati...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Nat Rev Clin Oncol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2013
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4665630/ https://ncbi.nlm.nih.gov/pubmed/23959269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2013.154 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|